Compositions comprising stem cells expressing mesenchymal and neuronal markers and uses thereof to treat neurological disease

Abstract

The present disclosure relates to a cryopreserved pharmaceutical composition comprising immature dental pulp stem cells (IDPSCs) expressing SOX-1 and SOX-2 and methods of treating a neurological disease or condition comprising systemically administering to a subject a cryopreserved pharmaceutical composition comprising IDPSCs expressing SOX-1 and SOX-2.

We claim: 
     
         1 . A cryopreserved pharmaceutical composition comprising immature dental pulp stem cells (IDPSCs), wherein the IDPSCs express SOX-1 and SOX-2. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the IDPSCs further express beta-3-tubulin. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the IDPSCs further express at least one marker selected from Oct3/4 and Nanog. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the IDPSCs are negative for HLA-ABC and HLA-DR major histocompatibility (MHC) antigens. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the IDPSCs are human IDPSCs. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is formulated for intravenous (IV) injection. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein the IDPSCs are cryopreserved with dimethyl sulfoxide (DMSO). 
     
     
         8 . A method of treating a neurological disease or condition comprising systemically administering to a subject in need thereof a cryopreserved pharmaceutical composition comprising immature dental pulp stem cells (IDPSCs), wherein the IDPSCs express SOX-1 and SOX-2. 
     
     
         9 . The method of  claim 8 , wherein the wherein the IDPSCs further express beta-3-tubulin. 
     
     
         10 . The method of  claim 9 , wherein the IDPSCs further express at least one marker selected from Oct3/4 and Nanog. 
     
     
         11 . The method of  claim 8 , wherein the IDPSCs are negative for HLA-ABC and HLA-DR major histocompatibility (MHC) antigens. 
     
     
         12 . The method of  claim 8 , wherein the pharmaceutical composition is intravenously administered to the subject. 
     
     
         13 . The method of  claim 8 , wherein the IDPSCs are autologous, allogeneic or both to the subject. 
     
     
         14 . The method of  claim 8 , wherein the neurological disease or condition is selected from the group consisting of Parkinson's disease (PD), multiple sclerosis, amyotrophic lateral sclerosis (ALS), stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatous neuropathy, Alzheimer's disease, and Huntington's disease (HD). 
     
     
         15 . The method of  claim 14 , wherein the neurological disease or condition is Huntington's disease (HD). 
     
     
         16 . The method of  claim 15 , wherein the subject is diagnosed with early HD and administering the hIDPSCs to the subject supports a neuroprotective mechanism in the subject. 
     
     
         17 . The method of  claim 14 , wherein the neurological disease or condition is Parkinson's disease (PD). 
     
     
         18 . The method of  claim 17 , wherein the subject is diagnosed with PD and administering the hIDPSCs to the subject repairs lost dopaminergic neurons in the subject. 
     
     
         19 . The method of  claim 8 , wherein the neurological disease or condition is selected from the group consisting of autism, schizophrenia, stroke, ischemia, a motor disorder, and a convulsive disorder. 
     
     
         20 . The method of  claim 8 , wherein the neurological disease or condition is selected from the group consisting of neuroblastoma and retinoblastoma.